Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity
•Rat diabetic retinopathy was associated was upregulated TLR4/NFκB expression.•Retinal glutamate and cytokine levels were elevated.•Metformin enhanced the retinal histopathological picture and ultrastructures.•Metformin downregulated TNF-α, VEGF andTLR4/NFκB expression.•Metformin reduced retinal glu...
Gespeichert in:
Veröffentlicht in: | International immunopharmacology 2021-01, Vol.90, p.107193, Article 107193 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 107193 |
container_title | International immunopharmacology |
container_volume | 90 |
creator | Alomar, Suliman Y. M. Barakat, Bassant Eldosoky, Mohamed Atef, Hoda Mohamed, Abdelaty Shawky Elhawary, Reda El-Shafey, Mohamed Youssef, Amal M. Elkazaz, Amany Y. Gabr, Attia M. Elaskary, Abdelhakeem A. Salih, Mohamed A.K. Alolayan, Sultan Othman Zaitone, Sawsan A. |
description | •Rat diabetic retinopathy was associated was upregulated TLR4/NFκB expression.•Retinal glutamate and cytokine levels were elevated.•Metformin enhanced the retinal histopathological picture and ultrastructures.•Metformin downregulated TNF-α, VEGF andTLR4/NFκB expression.•Metformin reduced retinal glutamate level.
Microvascular complications of diabetes mellitus are progressively significant reasons for mortality. Metformin (MET) is considered as the first-line therapy for type 2 diabetes patients, and may be especially beneficial in cases of diabetic retinopathy although the precise mechanisms of MET action are not fully elucidated. The current study was designed to inspect the antioxidant and modulatory actions of MET on DRET in streptozotocin-induced diabetic rats. The effect of MET on the toll-like receptor 4/nuclear factor kappa B (TLR4/NFkB), inflammatory burden and glutamate excitotoxicity was assessed. Twenty-four male rats were assigned to four experimental groups: (1) Vehicle group, (2) Diabetic control: developed diabetes by injection of streptozotocin (60 mg/kg, i.p.). (3&4) Diabetic + MET group: diabetic rats were left for 9 weeks without treatment and then received oral MET 100 and 200 mg/kg for 6 weeks. Retinal samples were utilized in biochemical, histological, immunohistochemical and electron microscopic studies. MET administration significantly decreased retinal level of insulin growth factor and significantly suppressed the diabetic induced increase of malondialdehyde, glutamate, tumor necrosis factor-α and vascular endothelial growth factor (VEGF). Further, MET decreased the retinal mRNA expression of NFkB, tumor necrosis factor-α and TLR4 in diabetic rats. The current findings shed the light on MET’s efficacy as an adjuvant therapy to hinder the development of diabetic retinopathy, at least partly, via inhibition of oxidative stress-induced NFkB/TLR4 pathway and suppression of glutamate excitotoxicity. |
doi_str_mv | 10.1016/j.intimp.2020.107193 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2491613262</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576920336602</els_id><sourcerecordid>2491613262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-bc2633879238de9b9144478a580d8c53bd74b61edd866a9f91a0518d8f05b6703</originalsourceid><addsrcrecordid>eNp9kc2OFCEUhYnROOPoGxhD4rp6oKCA2pjoZPxJJtGFrgkFt5SeKiiB6nS_jk8qnRpn6YZ7c_Kde4GD0GtKdpRQcb3f-VD8vOxa0p4lSXv2BF1SJVVDJeme1r4Tsumk6C_Qi5z3hFSd0-fogrGWC9XKS_TnW4oFbPEHwDCOtcNxxDOUMabZBxwDTqZg580AxVuc6hniYsqvE_bhEKcDZJzXZUmQs690dZc4Tc3k76HSFpYSE-bXYbUTmIRHY6vQ3OMPGI6PLhMc_jmtxcym1IscrS-xxKOv9fQSPRvNlOHVQ71CPz7efr_53Nx9_fTl5v1dY3knSjPYVjCmZN8y5aAfeso5l8p0ijhlOzY4yQdBwTklhOnHnhrSUeXUSLpBSMKu0Ntt7pLi7xVy0fu4plBX6pb3VFDWirZSfKNsijknGPWS_GzSSVOiz8Hovd6C0edg9BZMtb15GL4OM7hH078kKvBuA6A-8eAh6Ww9BAvO118s2kX__w1_AdkxpHc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2491613262</pqid></control><display><type>article</type><title>Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Alomar, Suliman Y. ; M. Barakat, Bassant ; Eldosoky, Mohamed ; Atef, Hoda ; Mohamed, Abdelaty Shawky ; Elhawary, Reda ; El-Shafey, Mohamed ; Youssef, Amal M. ; Elkazaz, Amany Y. ; Gabr, Attia M. ; Elaskary, Abdelhakeem A. ; Salih, Mohamed A.K. ; Alolayan, Sultan Othman ; Zaitone, Sawsan A.</creator><creatorcontrib>Alomar, Suliman Y. ; M. Barakat, Bassant ; Eldosoky, Mohamed ; Atef, Hoda ; Mohamed, Abdelaty Shawky ; Elhawary, Reda ; El-Shafey, Mohamed ; Youssef, Amal M. ; Elkazaz, Amany Y. ; Gabr, Attia M. ; Elaskary, Abdelhakeem A. ; Salih, Mohamed A.K. ; Alolayan, Sultan Othman ; Zaitone, Sawsan A.</creatorcontrib><description>•Rat diabetic retinopathy was associated was upregulated TLR4/NFκB expression.•Retinal glutamate and cytokine levels were elevated.•Metformin enhanced the retinal histopathological picture and ultrastructures.•Metformin downregulated TNF-α, VEGF andTLR4/NFκB expression.•Metformin reduced retinal glutamate level.
Microvascular complications of diabetes mellitus are progressively significant reasons for mortality. Metformin (MET) is considered as the first-line therapy for type 2 diabetes patients, and may be especially beneficial in cases of diabetic retinopathy although the precise mechanisms of MET action are not fully elucidated. The current study was designed to inspect the antioxidant and modulatory actions of MET on DRET in streptozotocin-induced diabetic rats. The effect of MET on the toll-like receptor 4/nuclear factor kappa B (TLR4/NFkB), inflammatory burden and glutamate excitotoxicity was assessed. Twenty-four male rats were assigned to four experimental groups: (1) Vehicle group, (2) Diabetic control: developed diabetes by injection of streptozotocin (60 mg/kg, i.p.). (3&4) Diabetic + MET group: diabetic rats were left for 9 weeks without treatment and then received oral MET 100 and 200 mg/kg for 6 weeks. Retinal samples were utilized in biochemical, histological, immunohistochemical and electron microscopic studies. MET administration significantly decreased retinal level of insulin growth factor and significantly suppressed the diabetic induced increase of malondialdehyde, glutamate, tumor necrosis factor-α and vascular endothelial growth factor (VEGF). Further, MET decreased the retinal mRNA expression of NFkB, tumor necrosis factor-α and TLR4 in diabetic rats. The current findings shed the light on MET’s efficacy as an adjuvant therapy to hinder the development of diabetic retinopathy, at least partly, via inhibition of oxidative stress-induced NFkB/TLR4 pathway and suppression of glutamate excitotoxicity.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2020.107193</identifier><identifier>PMID: 33246827</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antioxidants ; Complications ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Experimental - chemically induced ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - metabolism ; Diabetic retinopathy ; Diabetic Retinopathy - etiology ; Diabetic Retinopathy - metabolism ; Diabetic Retinopathy - pathology ; Diabetic Retinopathy - prevention & control ; Excitotoxicity ; Gene expression ; Glutamate excitotoxicity ; Glutamic Acid - metabolism ; Growth factors ; Hypoglycemic Agents - pharmacology ; Inflammation ; Insulin ; Male ; Malondialdehyde ; Metformin ; Metformin - pharmacology ; Microvasculature ; NF-kappa B - genetics ; NF-kappa B - metabolism ; NF-κB protein ; Oxidative stress ; Oxidative Stress - drug effects ; Rat diabetic retinopathy ; Rats ; Rats, Wistar ; Receptors ; Retina ; Retina - drug effects ; Retina - metabolism ; Retina - pathology ; Retinopathy ; Rodents ; Signal Transduction ; Streptozocin ; TLR4 protein ; TLR4/NFkB ; Toll-Like Receptor 4 - genetics ; Toll-Like Receptor 4 - metabolism ; Toll-like receptors ; Tumor Necrosis Factor-alpha - genetics ; Tumor Necrosis Factor-alpha - metabolism ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - metabolism</subject><ispartof>International immunopharmacology, 2021-01, Vol.90, p.107193, Article 107193</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV Jan 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-bc2633879238de9b9144478a580d8c53bd74b61edd866a9f91a0518d8f05b6703</citedby><cites>FETCH-LOGICAL-c456t-bc2633879238de9b9144478a580d8c53bd74b61edd866a9f91a0518d8f05b6703</cites><orcidid>0000-0002-9688-7683</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2020.107193$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33246827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alomar, Suliman Y.</creatorcontrib><creatorcontrib>M. Barakat, Bassant</creatorcontrib><creatorcontrib>Eldosoky, Mohamed</creatorcontrib><creatorcontrib>Atef, Hoda</creatorcontrib><creatorcontrib>Mohamed, Abdelaty Shawky</creatorcontrib><creatorcontrib>Elhawary, Reda</creatorcontrib><creatorcontrib>El-Shafey, Mohamed</creatorcontrib><creatorcontrib>Youssef, Amal M.</creatorcontrib><creatorcontrib>Elkazaz, Amany Y.</creatorcontrib><creatorcontrib>Gabr, Attia M.</creatorcontrib><creatorcontrib>Elaskary, Abdelhakeem A.</creatorcontrib><creatorcontrib>Salih, Mohamed A.K.</creatorcontrib><creatorcontrib>Alolayan, Sultan Othman</creatorcontrib><creatorcontrib>Zaitone, Sawsan A.</creatorcontrib><title>Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•Rat diabetic retinopathy was associated was upregulated TLR4/NFκB expression.•Retinal glutamate and cytokine levels were elevated.•Metformin enhanced the retinal histopathological picture and ultrastructures.•Metformin downregulated TNF-α, VEGF andTLR4/NFκB expression.•Metformin reduced retinal glutamate level.
Microvascular complications of diabetes mellitus are progressively significant reasons for mortality. Metformin (MET) is considered as the first-line therapy for type 2 diabetes patients, and may be especially beneficial in cases of diabetic retinopathy although the precise mechanisms of MET action are not fully elucidated. The current study was designed to inspect the antioxidant and modulatory actions of MET on DRET in streptozotocin-induced diabetic rats. The effect of MET on the toll-like receptor 4/nuclear factor kappa B (TLR4/NFkB), inflammatory burden and glutamate excitotoxicity was assessed. Twenty-four male rats were assigned to four experimental groups: (1) Vehicle group, (2) Diabetic control: developed diabetes by injection of streptozotocin (60 mg/kg, i.p.). (3&4) Diabetic + MET group: diabetic rats were left for 9 weeks without treatment and then received oral MET 100 and 200 mg/kg for 6 weeks. Retinal samples were utilized in biochemical, histological, immunohistochemical and electron microscopic studies. MET administration significantly decreased retinal level of insulin growth factor and significantly suppressed the diabetic induced increase of malondialdehyde, glutamate, tumor necrosis factor-α and vascular endothelial growth factor (VEGF). Further, MET decreased the retinal mRNA expression of NFkB, tumor necrosis factor-α and TLR4 in diabetic rats. The current findings shed the light on MET’s efficacy as an adjuvant therapy to hinder the development of diabetic retinopathy, at least partly, via inhibition of oxidative stress-induced NFkB/TLR4 pathway and suppression of glutamate excitotoxicity.</description><subject>Animals</subject><subject>Antioxidants</subject><subject>Complications</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Experimental - chemically induced</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - metabolism</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy - etiology</subject><subject>Diabetic Retinopathy - metabolism</subject><subject>Diabetic Retinopathy - pathology</subject><subject>Diabetic Retinopathy - prevention & control</subject><subject>Excitotoxicity</subject><subject>Gene expression</subject><subject>Glutamate excitotoxicity</subject><subject>Glutamic Acid - metabolism</subject><subject>Growth factors</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Inflammation</subject><subject>Insulin</subject><subject>Male</subject><subject>Malondialdehyde</subject><subject>Metformin</subject><subject>Metformin - pharmacology</subject><subject>Microvasculature</subject><subject>NF-kappa B - genetics</subject><subject>NF-kappa B - metabolism</subject><subject>NF-κB protein</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Rat diabetic retinopathy</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptors</subject><subject>Retina</subject><subject>Retina - drug effects</subject><subject>Retina - metabolism</subject><subject>Retina - pathology</subject><subject>Retinopathy</subject><subject>Rodents</subject><subject>Signal Transduction</subject><subject>Streptozocin</subject><subject>TLR4 protein</subject><subject>TLR4/NFkB</subject><subject>Toll-Like Receptor 4 - genetics</subject><subject>Toll-Like Receptor 4 - metabolism</subject><subject>Toll-like receptors</subject><subject>Tumor Necrosis Factor-alpha - genetics</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2OFCEUhYnROOPoGxhD4rp6oKCA2pjoZPxJJtGFrgkFt5SeKiiB6nS_jk8qnRpn6YZ7c_Kde4GD0GtKdpRQcb3f-VD8vOxa0p4lSXv2BF1SJVVDJeme1r4Tsumk6C_Qi5z3hFSd0-fogrGWC9XKS_TnW4oFbPEHwDCOtcNxxDOUMabZBxwDTqZg580AxVuc6hniYsqvE_bhEKcDZJzXZUmQs690dZc4Tc3k76HSFpYSE-bXYbUTmIRHY6vQ3OMPGI6PLhMc_jmtxcym1IscrS-xxKOv9fQSPRvNlOHVQ71CPz7efr_53Nx9_fTl5v1dY3knSjPYVjCmZN8y5aAfeso5l8p0ijhlOzY4yQdBwTklhOnHnhrSUeXUSLpBSMKu0Ntt7pLi7xVy0fu4plBX6pb3VFDWirZSfKNsijknGPWS_GzSSVOiz8Hovd6C0edg9BZMtb15GL4OM7hH078kKvBuA6A-8eAh6Ww9BAvO118s2kX__w1_AdkxpHc</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Alomar, Suliman Y.</creator><creator>M. Barakat, Bassant</creator><creator>Eldosoky, Mohamed</creator><creator>Atef, Hoda</creator><creator>Mohamed, Abdelaty Shawky</creator><creator>Elhawary, Reda</creator><creator>El-Shafey, Mohamed</creator><creator>Youssef, Amal M.</creator><creator>Elkazaz, Amany Y.</creator><creator>Gabr, Attia M.</creator><creator>Elaskary, Abdelhakeem A.</creator><creator>Salih, Mohamed A.K.</creator><creator>Alolayan, Sultan Othman</creator><creator>Zaitone, Sawsan A.</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-9688-7683</orcidid></search><sort><creationdate>202101</creationdate><title>Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity</title><author>Alomar, Suliman Y. ; M. Barakat, Bassant ; Eldosoky, Mohamed ; Atef, Hoda ; Mohamed, Abdelaty Shawky ; Elhawary, Reda ; El-Shafey, Mohamed ; Youssef, Amal M. ; Elkazaz, Amany Y. ; Gabr, Attia M. ; Elaskary, Abdelhakeem A. ; Salih, Mohamed A.K. ; Alolayan, Sultan Othman ; Zaitone, Sawsan A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-bc2633879238de9b9144478a580d8c53bd74b61edd866a9f91a0518d8f05b6703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Antioxidants</topic><topic>Complications</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Experimental - chemically induced</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - metabolism</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy - etiology</topic><topic>Diabetic Retinopathy - metabolism</topic><topic>Diabetic Retinopathy - pathology</topic><topic>Diabetic Retinopathy - prevention & control</topic><topic>Excitotoxicity</topic><topic>Gene expression</topic><topic>Glutamate excitotoxicity</topic><topic>Glutamic Acid - metabolism</topic><topic>Growth factors</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Inflammation</topic><topic>Insulin</topic><topic>Male</topic><topic>Malondialdehyde</topic><topic>Metformin</topic><topic>Metformin - pharmacology</topic><topic>Microvasculature</topic><topic>NF-kappa B - genetics</topic><topic>NF-kappa B - metabolism</topic><topic>NF-κB protein</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Rat diabetic retinopathy</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptors</topic><topic>Retina</topic><topic>Retina - drug effects</topic><topic>Retina - metabolism</topic><topic>Retina - pathology</topic><topic>Retinopathy</topic><topic>Rodents</topic><topic>Signal Transduction</topic><topic>Streptozocin</topic><topic>TLR4 protein</topic><topic>TLR4/NFkB</topic><topic>Toll-Like Receptor 4 - genetics</topic><topic>Toll-Like Receptor 4 - metabolism</topic><topic>Toll-like receptors</topic><topic>Tumor Necrosis Factor-alpha - genetics</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alomar, Suliman Y.</creatorcontrib><creatorcontrib>M. Barakat, Bassant</creatorcontrib><creatorcontrib>Eldosoky, Mohamed</creatorcontrib><creatorcontrib>Atef, Hoda</creatorcontrib><creatorcontrib>Mohamed, Abdelaty Shawky</creatorcontrib><creatorcontrib>Elhawary, Reda</creatorcontrib><creatorcontrib>El-Shafey, Mohamed</creatorcontrib><creatorcontrib>Youssef, Amal M.</creatorcontrib><creatorcontrib>Elkazaz, Amany Y.</creatorcontrib><creatorcontrib>Gabr, Attia M.</creatorcontrib><creatorcontrib>Elaskary, Abdelhakeem A.</creatorcontrib><creatorcontrib>Salih, Mohamed A.K.</creatorcontrib><creatorcontrib>Alolayan, Sultan Othman</creatorcontrib><creatorcontrib>Zaitone, Sawsan A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alomar, Suliman Y.</au><au>M. Barakat, Bassant</au><au>Eldosoky, Mohamed</au><au>Atef, Hoda</au><au>Mohamed, Abdelaty Shawky</au><au>Elhawary, Reda</au><au>El-Shafey, Mohamed</au><au>Youssef, Amal M.</au><au>Elkazaz, Amany Y.</au><au>Gabr, Attia M.</au><au>Elaskary, Abdelhakeem A.</au><au>Salih, Mohamed A.K.</au><au>Alolayan, Sultan Othman</au><au>Zaitone, Sawsan A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2021-01</date><risdate>2021</risdate><volume>90</volume><spage>107193</spage><pages>107193-</pages><artnum>107193</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•Rat diabetic retinopathy was associated was upregulated TLR4/NFκB expression.•Retinal glutamate and cytokine levels were elevated.•Metformin enhanced the retinal histopathological picture and ultrastructures.•Metformin downregulated TNF-α, VEGF andTLR4/NFκB expression.•Metformin reduced retinal glutamate level.
Microvascular complications of diabetes mellitus are progressively significant reasons for mortality. Metformin (MET) is considered as the first-line therapy for type 2 diabetes patients, and may be especially beneficial in cases of diabetic retinopathy although the precise mechanisms of MET action are not fully elucidated. The current study was designed to inspect the antioxidant and modulatory actions of MET on DRET in streptozotocin-induced diabetic rats. The effect of MET on the toll-like receptor 4/nuclear factor kappa B (TLR4/NFkB), inflammatory burden and glutamate excitotoxicity was assessed. Twenty-four male rats were assigned to four experimental groups: (1) Vehicle group, (2) Diabetic control: developed diabetes by injection of streptozotocin (60 mg/kg, i.p.). (3&4) Diabetic + MET group: diabetic rats were left for 9 weeks without treatment and then received oral MET 100 and 200 mg/kg for 6 weeks. Retinal samples were utilized in biochemical, histological, immunohistochemical and electron microscopic studies. MET administration significantly decreased retinal level of insulin growth factor and significantly suppressed the diabetic induced increase of malondialdehyde, glutamate, tumor necrosis factor-α and vascular endothelial growth factor (VEGF). Further, MET decreased the retinal mRNA expression of NFkB, tumor necrosis factor-α and TLR4 in diabetic rats. The current findings shed the light on MET’s efficacy as an adjuvant therapy to hinder the development of diabetic retinopathy, at least partly, via inhibition of oxidative stress-induced NFkB/TLR4 pathway and suppression of glutamate excitotoxicity.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33246827</pmid><doi>10.1016/j.intimp.2020.107193</doi><orcidid>https://orcid.org/0000-0002-9688-7683</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1567-5769 |
ispartof | International immunopharmacology, 2021-01, Vol.90, p.107193, Article 107193 |
issn | 1567-5769 1878-1705 |
language | eng |
recordid | cdi_proquest_journals_2491613262 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Antioxidants Complications Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Experimental - chemically induced Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - metabolism Diabetic retinopathy Diabetic Retinopathy - etiology Diabetic Retinopathy - metabolism Diabetic Retinopathy - pathology Diabetic Retinopathy - prevention & control Excitotoxicity Gene expression Glutamate excitotoxicity Glutamic Acid - metabolism Growth factors Hypoglycemic Agents - pharmacology Inflammation Insulin Male Malondialdehyde Metformin Metformin - pharmacology Microvasculature NF-kappa B - genetics NF-kappa B - metabolism NF-κB protein Oxidative stress Oxidative Stress - drug effects Rat diabetic retinopathy Rats Rats, Wistar Receptors Retina Retina - drug effects Retina - metabolism Retina - pathology Retinopathy Rodents Signal Transduction Streptozocin TLR4 protein TLR4/NFkB Toll-Like Receptor 4 - genetics Toll-Like Receptor 4 - metabolism Toll-like receptors Tumor Necrosis Factor-alpha - genetics Tumor Necrosis Factor-alpha - metabolism Tumor necrosis factor-TNF Tumor necrosis factor-α Vascular endothelial growth factor Vascular Endothelial Growth Factor A - metabolism |
title | Protective effect of metformin on rat diabetic retinopathy involves suppression of toll-like receptor 4/nuclear factor-k B expression and glutamate excitotoxicity |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T20%3A54%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20effect%20of%20metformin%20on%20rat%20diabetic%20retinopathy%20involves%20suppression%20of%20toll-like%20receptor%204/nuclear%20factor-k%20B%20expression%20and%20glutamate%20excitotoxicity&rft.jtitle=International%20immunopharmacology&rft.au=Alomar,%20Suliman%20Y.&rft.date=2021-01&rft.volume=90&rft.spage=107193&rft.pages=107193-&rft.artnum=107193&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2020.107193&rft_dat=%3Cproquest_cross%3E2491613262%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2491613262&rft_id=info:pmid/33246827&rft_els_id=S1567576920336602&rfr_iscdi=true |